Articles producció científica> Medicina i Cirurgia

Extended dual antiplatelet therapy after acute coronary syndrome in Spain: Results from the EPICOR study

  • Dades identificatives

    Identificador: PC:2624
    Autors:
    Bardají, A.Leal, M.Arrarte, V.Garcia-Moll, X.Pérez de Isla, L.Bueno, H.
    Resum:
    Filiació URV: SI
  • Altres:

    Autor segons l'article: Bardají, A.; Leal, M.; Arrarte, V.; Garcia-Moll, X.; Pérez de Isla, L.; Bueno, H.
    Departament: Medicina i Cirurgia
    Autor/s de la URV: BARDAJÍ RUIZ, ALFREDO; Leal, M.; Arrarte, V.; Garcia-Moll, X.; Pérez de Isla, L.; Bueno, H.
    Paraules clau: Coronary artery disease Acute coronary syndrome myocardial infarction
    Resum: Introduction: Real-world, country-specific studies of dual antiplatelet therapy (DAPT) duration among survivors of acute coronary syndrome (ACS) are important for improving long-term prognosis. Aims: To investigate DAPT duration after hospital discharge for ACS in Spain. Results: Data from patients enrolled in the Spanish cohort of the EPICOR (long-tErm follow-up of antithrombotic management Patterns In acute CORonary syndrome patients) study (NCT01171404) were analyzed for changes to antithrombotic medication up to 2 years postdischarge according to index event diagnosis and patient characteristics. Deaths, coronary events, and bleeding events were analyzed over the same period. Overall, a high proportion of patients remained on DAPT at 2 years (53.1%). Among patients who experienced any on-treatment bleeding event, almost two-thirds remained on DAPT at the end of follow-up. Patients >65 years, diabetic, or those that were medically managed were more likely to continue with DAPT until 2 years following discharge. At 2 years, the incidence of bleeding events requiring hospitalization was low compared with the incidence of coronary events (1.4% vs 6.6%). There was a numerical reduction in coronary events, but no increase in bleeding events, with DAPT continuation compared with single antiplatelet therapy. Conclusions: More than half of patients in this unselected cohort study remained on DAPT at 2 years following discharge for ACS. Continuation with DAPT was greater among patients with additional cardiovascular risk factors, which suggests that treating physicians in Spain prioritizes ischemic risk reduction over bleeding risk in patients with ACS, according to patient's risk profile.
    Grup de recerca: Grup de Recerca Biomèdica HJ23
    Àrees temàtiques: Health sciences Ciencias de la salud Ciències de la salut
    Accès a la llicència d'ús: https://creativecommons.org/licenses/by/3.0/es/
    ISSN: 1755-5914
    Identificador de l'autor: N/D; N/D; N/D; N/D; N/D; N/D
    Data d'alta del registre: 2017-03-28
    Volum de revista: 35
    Versió de l'article dipositat: info:eu-repo/semantics/publishedVersion
    Enllaç font original: https://onlinelibrary.wiley.com/doi/full/10.1111/1755-5922.12237
    URL Document de llicència: https://repositori.urv.cat/ca/proteccio-de-dades/
    DOI de l'article: 10.1111/1755-5922.12237
    Entitat: Universitat Rovira i Virgili
    Any de publicació de la revista: 2017
    Pàgina inicial: Art.num. e12237
    Tipus de publicació: Article Artículo Article
  • Paraules clau:

    Infart de miocardi
    Artèries coronàries -- Malalties
    Malalties coronàries
    Coronary artery disease
    Acute coronary syndrome
    myocardial infarction
    Health sciences
    Ciencias de la salud
    Ciències de la salut
    1755-5914
  • Documents:

  • Cerca a google

    Search to google scholar